The current stock price of CMND is 2.35 USD. In the past month the price decreased by -48.6%. In the past year, price decreased by -96.16%.
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 48.37 | 1.01T | ||
| JNJ | JOHNSON & JOHNSON | 19.69 | 492.44B | ||
| MRK | MERCK & CO. INC. | 12.55 | 274.34B | ||
| PFE | PFIZER INC | 7.96 | 144.87B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 8.52 | 113.72B | ||
| ZTS | ZOETIS INC | 20.06 | 56.04B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.77 | 23.19B | ||
| VTRS | VIATRIS INC | 5.48 | 14.70B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 24.45 | 11.66B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 8.54B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 5.53B | ||
| CRNX | CRINETICS PHARMACEUTICALS IN | N/A | 5.05B |
Clearmind Medicine Inc is a CA-based company operating in Pharmaceuticals industry. The company is headquartered in Vancouver, British Columbia. The company went IPO on 2021-08-10. Clearmind Medicine Inc. is a psychedelic pharmaceutical biotech company. The firm is focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorders. The firm researches and develops psychedelic-based compounds and attempts to commercialize them as regulated medicines, foods, or supplements. The Company’s intellectual portfolio consists of 19 patent families including 31 granted patents.
CLEARMIND MEDICINE INC
101-1220 West 6Th Avenue
Vancouver BRITISH COLUMBIA CA
Employees: 0
Phone: 16042601566
Clearmind Medicine Inc is a CA-based company operating in Pharmaceuticals industry. The company is headquartered in Vancouver, British Columbia. The company went IPO on 2021-08-10. Clearmind Medicine Inc. is a psychedelic pharmaceutical biotech company. The firm is focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorders. The firm researches and develops psychedelic-based compounds and attempts to commercialize them as regulated medicines, foods, or supplements. The Company’s intellectual portfolio consists of 19 patent families including 31 granted patents.
The current stock price of CMND is 2.35 USD. The price decreased by -3.29% in the last trading session.
CMND does not pay a dividend.
CMND has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
CMND stock is listed on the Nasdaq exchange.
ChartMill assigns a fundamental rating of 2 / 10 to CMND. The financial health of CMND is average, but there are quite some concerns on its profitability.
Over the last trailing twelve months CMND reported a non-GAAP Earnings per Share(EPS) of -25.83. The EPS decreased by -102.96% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -101.99% | ||
| ROE | -378.42% | ||
| Debt/Equity | 0 |